Coherus Oncology Expands Clinical Program and Reports Third Quarter Financial Results

November 7, 2025 - 04:23

Coherus Oncology has announced an expansion of its clinical program for CHS-114, a highly selective Treg depleter, to include colorectal cancer. This strategic move aims to broaden the therapeutic applications of its innovative treatment and potentially enhance patient outcomes in this challenging area of oncology.

For the third quarter of 2025, the company reported robust financial results, ending the period with cash, cash equivalents, and marketable securities totaling $191.7 million. This solid financial foundation positions Coherus for future growth and development in its clinical endeavors.

Additionally, the company reported net revenue from LOQTORZI® of $11.2 million, representing a 12% increase compared to the previous quarter. This growth reflects the increasing demand for its products and the effectiveness of its marketing strategies.

A conference call is scheduled for today at 5:00 p.m. Eastern Standard Time, where company executives will discuss these results in more detail and provide insights into future initiatives.